Apr 26, 2023 / 04:00PM GMT
Stephen Willey - Stifel, Nicolaus & Co., Inc. - Analyst
All right. Good afternoon, everyone. I'm Stephen Willey, one of the senior analysts here at Stifel. And glad to have with us from Viracta Therapeutics, CEO, Mark Rothera; and Chief Medical Officer, Lisa Rojkjaer.
I think Mark's going to give us a little bit of a brief overview of the company, and then I think we're going to get into some Q&A. (Conference Instructions)
But Mark and Lisa, I really appreciate you guys presenting here, and I'm going to turn it over to you.
Mark Rothera - Viracta Therapeutics, Inc. - President & CEO
Great. Well, firstly, Stephen, thank you very much for the invitation to the Targeted Oncology Days that Stifel's holding. It's great to be with you.
Maybe I'll just start by saying that Viracta is a targeted oncology company. It was founded in 2015 and has been a public company since 2021. And it's really all about targeting, treating, and preventing virus-associated cancers. That's our mission.
And perhaps, since this is the first
Viracta Therapeutics Inc at Stifel Targeted Oncology Days (Virtual) Transcript
Mar 07, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers